This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
article provides recommendations for the clinical management of key
adverse reactions reported with lorlatinib. Despite the advancement of
second‐generation anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitors (TKIs), the emergence of resistance and progression of
central nervous system metastases remain clinically significant problems
in ALK‐positive non‐small cell lung cancer. Lorlatinib is a potent,
brain‐penetrant, third‐generation, macrocyclic ALK/ROS1 TKI, with
broad‐spectrum potency against most known resistance mutations that can
develop during treatment with existing first‐ and second‐generation ALK
Patients with a
history of autoimmune diseases (AIDs) have not usually been included in
clinical trials with immune checkpoint inhibitors but are frequent in
clinical practice. This study quantifies the increased risk of
developing immune‐related adverse events (irAEs) in patients with
pre‐existing AIDs who had to be treated with anti‐programmed death‐1
immunotherapy. Nevertheless, their toxicities are mild and the incidence
of grade 3/4 irAEs is not significantly higher compared with those of
controls. These results will help clinicians in everyday practice,
improving their ability to offer a proper counselling to patients, in
order to offer an immunotherapy treatment even to patients with
pre‐existing autoimmune disease.